Download PDF
Drug Res (Stuttg) 2019; 69(10): 565-571
DOI: 10.1055/a-0950-9608
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Computational Drug-repositioning Approach Identifying Sirolimus as a Potential Therapeutic Option for Inflammatory Dilated Cardiomyopathy

Kyoko Shibata
1   Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
,
Toshinori Endo
2   Graduate School of Information Science and Technology, Hokkaido University, Sapporo, Japan
,
Yoshikazu Kuribayashi
1   Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
› Author Affiliations
Further Information

Publication History

received 07 January 2019

accepted 04 June 2019

Publication Date:
25 June 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Objective The aim of this study was to determine promising treatment options for human inflammatory dilated cardiomyopathy using a computational drug-repositioning approach (repurposing established drug compounds for new therapeutic indications).

Background If the myocardial tissue is detected to be infiltrated with inflammatory cells, primarily of lymphocytes, and if the virus is confirmed using genetic examination (PCR) or immunostaining, the infection is suspected. However, there is no specific treatment (i. e., an antiviral drug) even if the virus is identified; therefore, we used Connectivity Map to identify compounds showing inverse drug–disease signatures, indicating activity against inflammatory dilated cardiomyopathy.

Results Potential drug-repositioning candidates for the treatment of inflammatory dilated cardiomyopathy were explored through a systematic comparison of the gene expression profiles induced by drugs using Gene Expression Omnibus and Connectivity Map databases.

Conclusion Using a computational drug-repositioning approach based on the integration of publicly available gene expression signatures of drugs and diseases, sirolimus was suggested as a novel therapeutic option for inflammatory dilated cardiomyopathy.

Key words

inflammation dilated cardiomyopathy - connectivity map - gene expression omnibus - rapamycin
 

  • References

  • 1 Caforio AL, Pankuweit S, Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648
    CrossrefPubMedGoogle Scholar
  • 2 Karatolios K, Holzendorf V, Hatzis G. et al. Clinical predictors of outcome in patients with inflammatory dilated cardiomyopathy. PloS One 2017; 12: e0188491
    CrossrefPubMedGoogle Scholar
  • 3 Molina KM, Garcia X, Denfield SW. et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol 2013; 34: 390-397
    CrossrefPubMedGoogle Scholar
  • 4 Haupt VJ, Schroeder M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform 2011; 12: 312-326
    CrossrefPubMedGoogle Scholar
  • 5 Andronis C, Sharma A, Virvilis V. et al. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011; 12: 357-368
    CrossrefPubMedGoogle Scholar
  • 6 Lussier YA, Chen JL. The emergence of genome-based drug repositioning. Sci Transl Med 2011; 3: 96ps35
    PubMedGoogle Scholar
  • 7 Xu R, Wang Q. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. BMC Genomics 2016; 17: 518
    CrossrefPubMedGoogle Scholar
  • 8 Lamb J, Crawford ED, Peck D. et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935
    CrossrefPubMedGoogle Scholar
  • 9 Sirota M, Dudley JT, Kim J. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77
    PubMedGoogle Scholar
  • 10 Kindermann I, Barth C, Mahfoud F. et al. Update on myocarditis. J Am Coll Cardiol 2012; 5: 779-792
    PubMedGoogle Scholar
  • 11 Basso C, Calabrese F, Corrado D. et al. Postmortem diagnosis in sudden cardiac death victims: Macroscopic, microscopic and molecular findings. Cardiovasc Res 2001; 50: 290-300
    CrossrefPubMedGoogle Scholar
  • 12 Xie K, Jin B, Li Y. et al. Modulating autophagy improves cardiac function in a rat model of early-stage dilated cardiomyopathy. Cardiology 2013; 125: 60-68
    CrossrefPubMedGoogle Scholar
  • 13 Krejci J, Mlejnek D, Sochorova D. et al. Inflammatory cardiomyopathy: A current view on the pathophysiology, diagnosis, and treatment. Biomed Res Int 2016; 2016; 4087632
    PubMedGoogle Scholar
  • 14 Bohra R, Schöning W, Klawitter J. et al. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One 2012; 7: e48063
    CrossrefPubMedGoogle Scholar
  • 15 Bahk TJ, Daniels MD, Leon JS. et al. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol 2008; 125: 85-93
    CrossrefPubMedGoogle Scholar
  • 16 Song HK, Han DH, Song JH. et al. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats. Am J Transplant 2009; 9: 2024-2033
    CrossrefPubMedGoogle Scholar
  • 17 Saegusa S, Fei Y, Takahashi T. et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther 2007; 21: 155-160
    CrossrefPubMedGoogle Scholar
  • 18 Yuan Z, Shioji K, Kihara Y. et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: Anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286: H83-H90
    CrossrefPubMedGoogle Scholar
  • 19 Pauschinger M, Rutschow S, Chandrasekharan K. et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005; 7: 444-452
    CrossrefPubMedGoogle Scholar
  • 20 Xiao J, Shimada M, Liu W. et al. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur J Heart Fail 2009; 11: 349-353
    CrossrefPubMedGoogle Scholar
  • 21 Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-2625
    CrossrefPubMedGoogle Scholar
  • 22 Barrett T, Edgar R. Gene expression omnibus microarray data storage, submission, retrieval, and analysis. Methods Enzymol 2006; 411: 352-369
    PubMedGoogle Scholar
  • 23 Heinz-Peter S, Cornelia P, Olaf S. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016; 105: 763-773
    CrossrefPubMedGoogle Scholar
  • 24 Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210
    CrossrefPubMedGoogle Scholar
  • 25 Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121
    CrossrefPubMedGoogle Scholar
  • 26 Krakauer T, Buckley M, Issaq HJ. et al. Sirolimus protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 1125-1131
    CrossrefPubMedGoogle Scholar
  • 27 Kania G, Blyszczuk P, Müller-Edenborn B. et al. Novel therapeutic options in inflammatory cardiomyopathy. Swiss Med Wkly 2013; 143: 13841
    PubMedGoogle Scholar
  • 28 Krejci J, Mlejnek D, Sochorova D. et al. Inflammatory cardiomyopathy: A current view on the pathophysiology, diagnosis, and treatment. Biomed Res Int 2016; 4087632
    PubMedGoogle Scholar
  • 29 Maisch B, Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy: Focus on i. v. immunoglobulins. Herz 2018; 43: 423-430
    CrossrefPubMedGoogle Scholar